Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ).
Jiangsu Recbio Technology Co., Ltd. has received approval to expand its Drug Production License to include the recombinant shingles vaccine and its adjuvant components. This expansion enhances the company’s R&D and production capabilities, aligning with the growing market demand for shingles vaccines due to population aging. The approval signifies regulatory recognition of the company’s quality management and production standards, positioning it for future commercialization and strengthening its competitiveness in the biopharmaceutical industry.
The most recent analyst rating on (HK:2179) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of preventive biological products. The company specializes in vaccines, leveraging advanced technology to address infectious diseases, particularly in the aging population.
Average Trading Volume: 37,764
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.02B
See more data about 2179 stock on TipRanks’ Stock Analysis page.